Evidence Report: Licit Schedule II Drug Use and Commercial Motor Vehicle Driver Safety (Comprehensive Review)

NHTSA · 2006 · ROSA P / United States. Department of Transportation. Federal Motor Carrier Safety Administration

archive: archived pipeline: cataloged verified

Get this paper ↗ (full text — opens at the source; we link to it, we don't host it)

Summary

This 2006 evidence report, prepared by ECRI for the Federal Motor Carrier Safety Administration (FMCSA), examines the safety implications of licit Schedule II drug use among commercial motor vehicle (CMV) drivers. Motivated by the high fatality rate in the trucking industry and the need to refine regulatory standards, the study aims to determine whether prescribed Schedule II drugs—specifically opioids, stimulants, and depressants—increase crash risk or impair driving ability. The report addresses eight key questions regarding crash risk, indirect measures of driving ability (such as cognitive and psychomotor function), serum drug levels, pharmacokinetics, and drug interactions. The researchers conducted a comprehensive systematic review of literature from seven electronic databases through June 2006, supplemented by hand searches of gray literature and reference lists. Studies were evaluated against strict inclusion and exclusion criteria, with particular attention to distinguishing licit therapeutic use from illicit abuse. The quality of the evidence was graded based on study design, robustness, and generalizability. Because meta-analysis was deemed inappropriate, the findings are based on qualitative assessments of the available evidence bases for each key question. The report finds that the relationship between licit Schedule II drug use and actual motor vehicle crash risk cannot be determined due to a lack of studies that isolate licit users from illicit users. Regarding indirect measures of driving ability, data specific to CMV drivers are scarce. For opioids, first-time administration to opioid-naïve individuals moderately impairs psychomotor and high-level cognitive function, though findings on driving simulators are inconsistent and based on low-quality studies. Long-term opioid use shows mixed results, with some studies suggesting no deficit and others indicating potential impairment, but the evidence remains insufficient for definitive conclusions. For stimulants, the report notes a lack of data on long-term licit use and inconsistent findings regarding acute effects on driving ability. Similarly, for depressants, evidence is limited and often of low quality. The report concludes that while acute opioid use likely impairs certain cognitive functions, there is insufficient high-quality evidence to definitively link licit Schedule II drug use to increased crash risk or specific driving deficits in CMV operators. These findings highlight significant gaps in the scientific literature, suggesting that current regulatory decisions may rely on incomplete data.

Key finding

First-time administration of therapeutic doses of Schedule II opioids adversely affects psychomotor and high-level cognitive function in opioid-naive individuals, while therapeutic doses of Schedule II stimulants improve driving performance and cognitive function in individuals with attention deficit hyperactivity disorder.

Methodology

review

Provenance

The full processing record for this entry. Every stage of this paper's journey through the pipeline is logged — what ran, with which tool and model, how many attempts it took, and when it last completed. Discovered via bulk_ingest_rosap on 2026-05-23 (6 acquisition events logged).

Summary generated by qwen3.6-27b-prismaquant on 2026-06-10; verification: verified.

Topics

Ranked by relevance to this paper. Hover a topic for its definition.

• opioids
• illicit drugs
• prescription meds
• polydrug
• cannabis
• truck driver fatigue

Information type

What kind of knowledge this paper contributes, grouped by family — independent of topic (what it is about) and method (how it was studied).

• Empirical Findings: observational prevalence
• Methodological Resource: validation psychometrics